Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 36Neoplasms 32Prostatic Neoplasms 26Colorectal Neoplasms 25Lung Neoplasms 21Carcinoma, Non-Small-Cell Lung 16Hematologic Neoplasms 13Neoplasm Metastasis 10Pancreatic Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Hematopoietic and Lymphatic System Neoplasm 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Anatomic Stage I Breast Cancer AJCC v8 6Uterine Cervical Neoplasms 5Sarcoma 5Glioma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Mouth Neoplasms 4Motor Activity 4Melanoma 4Leukemia, Myeloid, Acute 4Hematopoietic and Lymphoid System Neoplasm 4Head and Neck Carcinoma 4Gastrointestinal Neoplasms 4

Interventions

trifluridine tipiracil drug combination 1pembrolizumab 1Trifluridine 1Standard of Care 1Injections 1HMPL-013 1Fulvestrant 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced/Metastatic Solid Tumors × Standard of Care × 1 year × Clear all
NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Recruiting
186 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡